Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: Nationally representative cross sectional study

BMJ (Online)

Volumn 362, Issue , 2018, Pages

  Khera, Rohan ^a   Lu, Yuan ^b   Lu, Jiapeng ^c   Saxena, Anshul ^d   Nasir, Khurram ^b,e   Jiang, Lixin ^c   Krumholz, Harlan M ^b,e,f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c FUWAI HOSPITAL   (China)

^d MIAMI CANCER INSTITUTE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHINA; CORONARY ARTERY ATHEROSCLEROSIS; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MANAGEMENT; FEMALE; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UNITED STATES; HEALTH CARE POLICY; LONGITUDINAL STUDY; MEDICAL SOCIETY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT;

AGED; AMERICAN HEART ASSOCIATION; ANTIHYPERTENSIVE AGENTS; CHINA; CROSS-SECTIONAL STUDIES; ELIGIBILITY DETERMINATION; FEMALE; HEALTH POLICY; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; UNITED STATES;

EID: 85050242065     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.k2357     Document Type: Article

References (59)

1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71: e127-248. doi: 10.1016/j.jacc.2017.11.006
2. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-20. doi: 10.1001/jama.2013.284427
3. Wilt TJ, Kansagara D, Qaseem A, Clinical Guidelines Committee of the American College of Physicians. Hypertension limbo: balancing benefits, harms, and patient preferences before we lower the bar on blood pressure. Ann Intern Med 2018; 168: 369-70. doi: 10.7326/M17-3293
4. Crawford C. AAFP decides to not endorse AHA/ACC hypertension guideline: Academy continues to endorse JNC8 guideline. 2017. https://www.aafp.org/news/health-of-Thepublic/20171212notendorseaha-Accgdlne.html
5. Lonn EM, Bosch J, López-Jaramillo P, et al, HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374: 2009-20. doi: 10.1056/NEJMoa1600175
6. Musini VM, Gueyffier F, Puil L, Salzwedel DM, Wright JM. Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database Syst Rev 2017; 8: CD008276.
7. Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev 2012; 8: CD006742.
8. Mechanic D. Illness behaviour: An overview. Springer, 1986: 10.1007/978-1-4684-5257-0-6.
9. Wallis EJ, Ramsay LE, Jackson PR. Cardiovascular and coronary risk estimation in hypertension management. Heart 2002; 88: 306-12. doi: 10.1136/heart.88.3.306
10. Bakris G, Sorrentino M. Redefining hypertension -Assessing the new blood-pressure guidelines. N Engl J Med 2018; 378: 497-9.doi: 10.1056/NEJMp1716193
11. Krumholz HM. Blood pressure guidelines as starting point in clinical decisions. BMJ 2018; 360: j5862. doi: 10.1136/bmj.j5862
12. Muntner P, Carey RM, Gidding S, et al. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation 2017; 71: 109-18.
13. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004; 164: 2126-34. doi: 10.1001/archinte.164.19.2126
14. Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA 2014; 311: 1424-9. doi: 10.1001/jama.2014.2531
15. Murthy VL, Shah RV, Rubenfire M, Brook RD. Comparison of the Treatment Implications of American Society of Hypertension and International Society of Hypertension 2013 and Eighth Joint National Committee Guidelines: An analysis of National Health and Nutrition Examination Survey. Hypertension 2014; 64: 275-80. doi: 10.1161/HYPERTENSIONAHA.114.03703
16. Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 17 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet 2017; 390: 2549-58. doi: 10.1016/S0140-6736(17)32478-9
17. Su M, Zhang Q, Bai X, et al. Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: A nationwide cross-sectional survey. Lancet 2017; 390: 2559-68. doi: 10.1016/S0140-6736(17)32476-5
18. Lu Y, Wang P, Zhou T, et al. Comparison of prevalence, awareness, treatment, and control of cardiovascular risk factors in China and the United States. J Am Heart Assoc 2018; 7: e007462. doi: 10.1161/JAHA.117.007462
19. National Institute on Aging, National Natural Science Foundation of China, World Bank. China Health and Retirement Longitudinal Study. http://charls.pku.edu.cn/en.
20. Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS). Int J Epidemiol 2014; 43: 61-8. doi: 10.1093/ije/dys203
21. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303: 2043-50. doi: 10.1001/jama.2010.650
22. Wang JG. Chinese Hypertension Guidelines. Pulse (Basel) 2015; 3: 14-20. doi: 10.1159/000382025
23. Writing group of 2010 Chinese Guidelines for the management of hypertension. 2010 Chinese guidelines for the management of hypertension. Chin J Hypertens 2011; 19: 701-43.
24. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(Suppl 2): S49-73. doi: 10.1161/01. cir.0000437741.48606.98
25. Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pressure target after SPRINT: insights from a network meta-Analysis of randomized trials. Am J Med 2017; 130: 707-719.e8. doi: 10.1016/j.amjmed.2017.01.004
26. Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: A systematic review and network meta-Analysis. JAMA Cardiol 2017; 2: 775-81. doi: 10.1001/jamacardio.2017.1421
27. Wright JTJr, Williamson JD, Whelton PK, et al, SPRINT Research Group. A randomized trial of intensive versus standard bloodpressure control. N Engl J Med 2015; 373: 2103-16. doi: 10.1056/NEJMoa1511939
28. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479-86. doi: 10.1056/NEJMoa010273
29. Kassaï B, Boissel JP, Cucherat M, Boutitie F, Gueyffier F. Treatment of high blood pressure and gain in event-free life expectancy. Vasc Health Risk Manag 2005; 1: 163-9. doi: 10.2147/vhrm.1.2.163.64086
30. Reboussin DM, Allen NB, Griswold ME, et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: e116-35. doi: 10.1161/HYP.0000000000000067
31. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: 1269-324. doi: 10.1161/HYP.0000000000000066
32. Cushman WC, Evans GW, Byington RP, et al, ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-85. doi: 10.1056/NEJMoa1001286
33. Patel A, MacMahon S, Chalmers J, et al, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007; 370: 829-40. doi: 10.1016/S0140-6736(07)61303-8
34. Ridker PM, Cook NR. The pooled cohort equations 3 years on: building a stronger foundation. Circulation 2016; 134: 1789-91. doi: 10.1161/CIRCULATIONAHA.116.024246
35. Ridker PM, Cook NR. Comparing cardiovascular risk prediction scores. Ann Intern Med 2015; 162: 313-4. doi: 10.7326/M14-2820
36. Loprinzi PD, Addoh O. Predictive validity of the American College of Cardiology/American Heart Association pooled cohort equations in predicting all-cause and cardiovascular disease-specific mortality in a national prospective cohort study of adults in the United States. Mayo Clin Proc 2016; 91: 763-9. doi: 10.1016/j.mayocp.2016.03.019
37. Emdin CA, Khera AV, Natarajan P, et al. Evaluation of the pooled cohort equations for prediction of cardiovascular risk in a contemporary prospective cohort. Am J Cardiol 2017; 119: 881-5. doi: 10.1016/j.amjcard.2016.11.042
38. Zhang Z, Gillespie C, Bowman B, Yang Q. Prediction of atherosclerotic cardiovascular disease mortality in a nationally representative cohort using a set of risk factors from pooled cohort risk equations. PLoS One 2017; 12: e0175822. doi: 10.1371/journal. pone.0175822
39. Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014; 311: 1416-23. doi: 10.1001/jama.2014.2632
40. Shum K, Zheng P, Dinh T, et al. Recommended use of the pooled cohort equations over-estimates cardiovascular risk in hispanics: evidence from the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT)and the multi-ethnic study of atherosclerosis (MESA). Circulation 2014; 130(Suppl 2): A19716.
41. Lee CH, Woo YC, Lam JKY, et al. Validation of the Pooled Cohort equations in a long-Term cohort study of Hong Kong Chinese. J Clin Lipidol 2015; 9: 640-6.e2. doi: 10.1016/j.jacl.2015.06.005
42. Vilaiwatanakorn K, Vathesatogkit P, Yingchoncharoen T, et al. Accuracy of 10 year-risk calculation for first atherosclerotic cardiovascular event from new pooled cohort equations and WHO risk calculation in EGAT population. Eur Heart J 2015; 36: 805.
43. DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J 2017; 38: 598-608.
44. Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol 2016; 67: 2118-30. doi: 10.1016/j.jacc.2016.02.055
45. Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006; 98: 204-8. doi: 10.1016/j.amjcard.2006.01.079
46. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 2012; 126: 2105-14. doi: 10.1161/CIRCULATIONAHA.112.096156
47. Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation 2006; 113: 213-21. doi: 10.1161/CIRCULATIONAHA.105.542290
48. Jackson JH, Sobolski J, Krienke R, Wong KS, Frech-Tamas F, Nightengale B. Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines. J Am Board Fam Med 2008; 21: 512-21. doi: 10.3122/jabfm.2008.06.080025
49. Keenan NL, Rosendorf KA, Centers for Disease Control and Prevention (CDC). Prevalence of hypertension and controlled hypertension -United States, 2005-2008. MMWR Suppl 2011; 60(1): 94-7.
50. Sakhuja A, Textor SC, Taler SJ. Uncontrolled hypertension by the 2014 evidence-based guideline: results from NHANES 2011-2012. J Hypertens 2015; 33: 644-51, discussion 652. doi: 10.1097/HJH.0000000000000442
51. Khera R, Lu Y, Saxena A, et al. The impact of 2017 ACC/AHA guidelines on the prevalence of hypertension and eligibility for antihypertensive therapy in the United States and China. bioRxiv 2017. doi: 10.1101/218859.
52. Mancia G, Corrao G. Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From Italy. Circulation 2018; 137: 889-90. doi: 10.1161/CIRCULATIONAHA.117.032850
53. Brunström M, Carlberg B, Lindholm LH. Perspective From Sweden on the Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A "Sprint" Beyond Evidence in the United States. Circulation 2018; 137: 886-8. doi: 10.1161/CIRCULATIONAHA.118.033632
54. Schiffrin EL. Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From Canada. Circulation 2018; 137: 883-5. doi: 10.1161/CIRCULATIONAHA.117.032849
55. Wander GS, Ram CVS. Global Impact of 2017 American Heart Association/American College of Cardiology Hypertension Guidelines: A Perspective From India. Circulation 2018; 137: 549-50. doi: 10.1161/CIRCULATIONAHA.117.032877
56. Wang JG, Liu L. Global Impact of 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From China. Circulation 2018; 137: 546-8. doi: 10.1161/CIRCULATIONAHA.117.032890
57. Kario K. Global Impact of 2017 American Heart Association/American College of Cardiology Hypertension Guidelines: A Perspective From Japan. Circulation 2018; 137: 543-5. doi: 10.1161/CIRCULATIONAHA.117.032851
58. Wang Z, Chen Z, Zhang L, et al, China Hypertension Survey Investigators. Status of hypertension in China: results from the China Hypertension Survey, 2012-2015. Circulation 2018; 137: 2344-56. doi: 10.1161/CIRCULATIONAHA.117.032380
59. Chobanian AV, Bakris GL, Black HR, et al, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureNational High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72. doi: 10.1001/jama.289.19.2560